The Efficacy of High- and Low-Dose Intravenous Omeprazole in Preventing Rebleeding for Patients with Bleeding Peptic Ulcers and Comorbid Illnesses
This study sought to determine if high-dose omeprazole infusion could improve the control of rebleeding in patients with comorbid illnesses and bleeding peptic ulcers. After achieving hemostasis by endoscopy, 105 patients were randomized into high-dose (n = 52) and low-dose (n = 53) groups, receiving 200 and 80 mg/day omeprazole, respectively, as a continuous infusion for 3 days.
Thereafter, oral omeprazole, 20 mg/day, was given. The cumulative rebleeding rates comparatively rose in both groups (high-dose vs. low-dose group), beginning on day 3 (15.4% vs. 11.3%), day 7 (19.6% vs. 20%), and day 14 (32.7% vs. 28.9%), until day 28 (35.4% vs. 33.3%), and were not significantly different between the two groups (P > 0.50). Multiple logistic regression confirmed that a serum albumin level < 3 g/dL was an independent factor associated with rebleeding (P = 0.002). For patients with comorbidities, 3-day omeprazole infusion, despite increasing the daily dose from 80 to 200 mg, was not adequate to control peptic ulcer rebleeding.
Key Wordspeptic ulcer bleeding comorbid illnesses omeprazole infusion hypoalbuminemia
Unable to display preview. Download preview PDF.
- 3.Jensen DM, Kovacs TOG, Randall GM, Machicado GA, Jensen ME, You S, Pelayo E: Prospective study of patients who developed severe ulcer bleeding as inpatients compared to outpatients. Gastrointest Endosc 38:235 (A38), 1992 (abstract)Google Scholar
- 6.Schaffalitzky de Muckadell OB, Havelund T, Harling H, Boesby S, Snel P, Vreeburg EM, Eriksson S, Fernström P, Hasselgren G: Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers: Randomized double-blind placebo-controlled multicentre study. Scand J Gastroenterol 32:320–327, 1997PubMedGoogle Scholar
- 7.Sheu BS, Chi CH, Huang CC, Kao AW, Wang YL, Yang HB: Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding. Aliment Pharmacol Ther 16:137–143, 2002Google Scholar
- 9.Bertilsson L: Geographic/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29:192–209, 1995Google Scholar
- 12.American Society of Anesthesiologists: New classification of physical status. Anesthesiology 24:111, 1963Google Scholar
- 13.Siringo S, Santoro P, Merighi S, Difebo G, McCormick PA, McIntyre N, Barbara L, Burroughs AK: Peptic ulceration and its complications in cirrhosis: an endoscopic and clinical survey in 2047 patients. Gut 31:A628, 1990 (abstract)Google Scholar
- 15.Cappell MS, Nadler SC: Increased mortality of acute upper gastrointestinal bleeding in patients with chronic obstructive pulmonary disease. A case controlled, multiyear study of 53 consecutive patients. Dig Dis Sci 40:256–262, 1995Google Scholar
- 18.Freston JW: Overview of medical therapy of peptic ulcer disease. Gastroenterol Clin North Am 9:121–140, 1990Google Scholar
- 20.Udd M, Miettinen P, Palmu A, Heikkinen M, Janatuinen E, Pasanen P, Tarvainen R, Kairaluoma MV, Lohman M, Mustonen H, Julkunen R: Regular-dose versus high-dose omeprazole in peptic ulcer bleeding: a prospective randomized double-blind study. Scand J Gastroenterol 36:1332–1338, 2001PubMedGoogle Scholar
- 23.Tarnawski A: Cellular mechanisms of gastric ulcer healing. In The Stomach. W Domschke, SJ Konturek (eds). Berlin, Springer-Verlag, 1993, pp 177–192Google Scholar
- 24.Tarnawski A: Cellular and molecular mechanisms of ulcer healing. Drugs Today 33:697–706, 1997Google Scholar